Comparative immunogenicity assessment Review
www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/WC500003946.pdf.
12 US Food and Drug Administration. Guidance for industry – assay development for immunogenicity testing of therapeutic proteins (Draft guidance).
www.fda.gov/downloads/Drugs/ Guidances/UCM192750.pdf.
13 Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48, 1267–1281 (2008).
14 Cai XY, Gouty D, Baughman S et al. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development. Bioanalysis 3(5), 535–540 (2011).
15 Cai XY, Thomas J, Cullen C et al. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development. Bioanalysis 4(17), 2169–2177 (2012).
16 European Bioanalysis Forum. Outcome of EBF Survey on Biosimilars.
http://bcn2012.europeanbioanalysisforum.eu/slides/ day%202/ii%20biosimilars/2_munday.pdf.
17 US Food and Drug Administration. Guidance for industry – immunogenicity assessment for therapeutic proteins (Draft guidance).
www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ ucm338856.pdf.
18 Christine HC, Mirakhur B, Chan E et al. Cetuximab- induced anaphylaxis and IgE specific for galactose-α-1,3- Galactose. N. Engl. J. Med. 358(11), 1109–1117 (2008).
19 Barbosa MDFS. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov. Today 16(7-8), 345–353 (2011).
20 Hoffmann S, Cepok S, Grummel V et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-b therapy in multiple sclerosis. Am. J. Hum. Genet. 83, 219–227 (2008).
21 Qiu ZJ, Ying Y, Fox M et al. A novel homogeneous biotin– digoxigenin based assay for the detection of human anti- therapeutic antibodies in autoimmune serum. J. Immunol. Methods 362, 101–111 (2010).
22 Jaki T, Lawo JP, Wolfsegger MJ et al. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays. J. Pharm. Biomed. Anal. 55(5), 1148–1156 (2011).
23 Shankar G, Arkin S, Cocea L et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides – harmonized terminology and tactical recommendations. AAPS J. 16(4), 658–673 (2014).
future science group
www.future-science.com
381
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154